Danaher Nears $10B Masimo Acquisition
Global medtech company Danaher is reportedly closing in on a deal to acquire medical monitoring firm Masimo for nearly $10 billion. The acquisition would be the largest in the medical technology sector of 2026. Financial media reports indicate the deal underscores the strategic value of diagnostic and patient monitoring platforms.
- Danaher's acquisition strategy is central to its growth, having acquired hundreds of businesses since 1984. The company utilizes a post-acquisition integration methodology known as the Danaher Business System (DBS), which is based on lean manufacturing principles, to improve operational efficiency in the companies it acquires. - This deal would significantly expand Danaher's Diagnostics segment, which accounted for 41% of the company's $23.9 billion in revenue in 2024. Danaher's recent major acquisitions have been in the life sciences and diagnostics space, including the $21.4 billion purchase of GE's biopharma business (now Cytiva) in 2020 and the $9.6 billion acquisition of Aldevron in 2021. - Masimo has recently undergone significant corporate turmoil, making it a potential acquisition target. Activist investor Politan Capital Management, which owns a nearly 9% stake, successfully replaced founder and CEO Joe Kiani on the board in 2024 after a two-year battle. The conflict was spurred by Masimo's controversial $1 billion acquisition of consumer audio company Sound United in 2022, which was seen as a departure from its core medical technology business. - The acquisition taps into the rapidly growing patient monitoring market, which is being driven by a shift to remote and home-based care. The global remote patient monitoring market was estimated at $14 billion in 2023 and is projected to reach over $41 billion by 2028. - This move aligns with broader healthcare M&A trends that favor consolidation in outpatient and services-driven sectors. In 2025, healthcare services was the most active subsector for M&A, as buyers pursued platforms with strong outpatient footprints. - The deal reflects a strategic focus on technologies that support care outside of traditional hospital settings. This site-of-care shift is influenced by reimbursement policies, such as Medicare's site-neutral payment rules, designed to counter higher fees charged by hospital-owned outpatient facilities. - For Danaher, acquiring Masimo's portfolio of non-invasive monitoring technologies, including its flagship SET pulse oximetry, provides a strong base of recurring revenue from sensors and consumables. In 2024, 81% of Danaher's revenue was from recurring sources.
